Compare RDIB & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RDIB | AKBA |
|---|---|---|
| Founded | 1937 | 2007 |
| Country | United States | United States |
| Employees | 2025 | N/A |
| Industry | Movies/Entertainment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 224.9M | 251.0M |
| IPO Year | N/A | 2014 |
| Metric | RDIB | AKBA |
|---|---|---|
| Price | $8.51 | $1.05 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $4.67 |
| AVG Volume (30 Days) | 3.2K | ★ 5.2M |
| Earning Date | 05-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 93.94 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $16.25 | N/A |
| Revenue Next Year | $4.04 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.10 | $0.82 |
| 52 Week High | $17.40 | $4.08 |
| Indicator | RDIB | AKBA |
|---|---|---|
| Relative Strength Index (RSI) | 41.27 | 49.02 |
| Support Level | N/A | $0.85 |
| Resistance Level | $12.53 | $1.56 |
| Average True Range (ATR) | 0.48 | 0.07 |
| MACD | -0.02 | 0.03 |
| Stochastic Oscillator | 17.90 | 66.91 |
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial and live theater assets.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.